Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.67 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.67 |
| ▸ | CHRNG | P07510 | 1/20 | 0.67 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.67 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.67 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.67 |
| ▸ | CHRND | Q07001 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359672 | 1.00 | CHRNB4 (0.67) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6359475 | 0.86 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL6359473 | 0.86 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL6357491 | 0.82 | CHRNB2 (0.56) | CHRNB4CHRNA3SLC6A4SLC6A3CHRNA1 | |
| SCHEMBL6360098 | 0.82 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL6360102 | 0.82 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL6362732 | 0.82 | KDM1A (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL6357489 | 0.82 | CHRNB2 (0.56) | CHRNB4CHRNA3SLC6A4SLC6A3CHRNA1 | |
| SCHEMBL6358996 | 0.79 | KDM1A (0.57) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6358995 | 0.79 | KDM1A (0.57) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1439836-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030236405-A1 | A nicotinic acetylcholine receptors, treating neurological and psychological disorders inflamnmatory bowel disease, irritable bowel syndrome, spastic dystonia, pain, vasoconstriction, anxiety, autism, depression, bipolar disorder | YOHANNES DANIEL (US) | 2003-12-25 | — | — | US | disclosed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003037329-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020038028-A1 | For therapy of neurological and psychological disorders are claimed. | YOHANNES DANIEL (US) | 2002-03-28 | — | — | US | disclosed |
| US-20020035262-A1 | 7-hetero-bicyclo[2.2.1]-heptanes | YOHANNES DANIEL (US) | 2002-03-21 | — | — | US | disclosed |
| EP-0955301-A2 | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors | Pfizer Products Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038028-A1 | For therapy of neurological and psychological disorders are claimed. | GRIN2C, PNMT, GRIA4 | CHRNB4 162/4885CHRNA3 183/4885SLC6A2 49/4885 |
| US-20030236405-A1 | A nicotinic acetylcholine receptors, treating neurological and psychological disorders inflamnmatory bowel disease, irritable bowel syndrome, spastic dystonia, pain, vasoconstriction, anxiety, autism, depression, bipolar disorder | CHRNA1, CHRNA6, CHRNA2 | CHRNB4 19/4885CHRNA3 7/4885SLC6A2 121/4885 |
| US-20020035262-A1 | 7-hetero-bicyclo[2.2.1]-heptanes | GRIN2C, CYP8B1, CYP11B2 | CHRNB4 206/4885CHRNA3 211/4885SLC6A2 767/4885 |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA7 | CHRNB4 20/4885CHRNA3 6/4885SLC6A2 153/4885 |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | CHRNB4 20/4885CHRNA3 7/4885SLC6A2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.